Intraperitoneal melatonin is not neuroprotective in the G93ASOD1 transgenic mouse model of familial ALS and may exacerbate neurodegeneration
- Autores
- Dardiotis, Efthimios; Panayiotou, Elena; Feldman, Mariana Laura; Hadjisavvas, Andreas; Malas, Stavros; Vonta, Ilia; Hadjigeorgiou, Georgios; Kyriakou, Kyriakos; Kyriakides, Theodoros
- Año de publicación
- 2013
- Idioma
- inglés
- Tipo de recurso
- artículo
- Estado
- versión publicada
- Descripción
- In amyotrophic lateral sclerosis (ALS) reactive oxygen species and apoptosis are implicated in disease pathogenesis. Melatonin with its anti-oxidant and anti-apoptotic properties is expected to ameliorate disease phenotype. The aim of this study was to assess possible neuroprotection of melatonin in the G93A-copper/zinc superoxide dismutase (G93ASOD1) transgenic mouse model of ALS. Four groups of mice, 14 animals each, were injected intraperitoneally with 0 mg/kg, 0.5 mg/kg, 2.5 mg/kg and 50 mg/kg of melatonin from age 40 days. The primary end points were; disease onset, disease duration, survival and rotarod performance. No statistically significant difference in disease onset between the four groups was found. Survival was significantly reduced with the 0.5 mg/kg and 50 mg/kg doses and tended to be reduced with the 2.5 mg/kg dose. Histological analysis of spinal cords revealed increased motoneuron loss in melatonin treated mice. Melatonin treated animals were associated with increased oxidative stress as assessed with 4-hydroxynonenal (4-HNE), a marker of lipid peroxidation. Histochemistry and Western blot data of spinal cord from melatonin treated mice revealed upregulation of human SOD1 compared to untreated mice. In addition, real-time PCR revealed a dose dependent upregulation of human SOD1 in melatonin treated animals. Thus, intraperitoneal melatonin, at the doses used, does not ameliorate and perhaps exacerbates phenotype in the G93ASOD1 mouse ALS model. This is probably due to melatonin's effect on upregulating gene expression of human toxic SOD1. This action presumably overrides any of its direct anti-oxidant and anti-apoptotic properties.
Fil: Dardiotis, Efthimios . The Cyprus Institute of Neurology and Genetics; Chipre
Fil: Panayiotou, Elena . The Cyprus Institute of Neurology and Genetics; Chipre
Fil: Feldman, Mariana Laura. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Córdoba. Instituto de Investigaciones Biológicas y Tecnológicas; Argentina
Fil: Hadjisavvas, Andreas . The Cyprus Institute of Neurology and Genetics; Chipre
Fil: Malas, Stavros . The Cyprus Institute of Neurology and Genetics; Chipre
Fil: Vonta, Ilia. National Technical University of Athens; Grecia
Fil: Hadjigeorgiou, Georgios . Centre for Research and Technology-Thessaly; Grecia
Fil: Kyriakou, Kyriakos . The Cyprus Institute of Neurology and Genetics; Chipre
Fil: Kyriakides, Theodoros . The Cyprus Institute of Neurology and Genetics; Chipre - Materia
-
Amyotrophic Lateral Sclerosis
G93asod1 Transgenic Mouse Model
Melatonin
Neuroprotection
Oxidative Stress - Nivel de accesibilidad
- acceso abierto
- Condiciones de uso
- https://creativecommons.org/licenses/by-nc-nd/2.5/ar/
- Repositorio
- Institución
- Consejo Nacional de Investigaciones Científicas y Técnicas
- OAI Identificador
- oai:ri.conicet.gov.ar:11336/13048
Ver los metadatos del registro completo
id |
CONICETDig_e30371608b478e0d6ad1a3881b29e16d |
---|---|
oai_identifier_str |
oai:ri.conicet.gov.ar:11336/13048 |
network_acronym_str |
CONICETDig |
repository_id_str |
3498 |
network_name_str |
CONICET Digital (CONICET) |
spelling |
Intraperitoneal melatonin is not neuroprotective in the G93ASOD1 transgenic mouse model of familial ALS and may exacerbate neurodegenerationDardiotis, Efthimios Panayiotou, Elena Feldman, Mariana LauraHadjisavvas, Andreas Malas, Stavros Vonta, IliaHadjigeorgiou, Georgios Kyriakou, Kyriakos Kyriakides, Theodoros Amyotrophic Lateral SclerosisG93asod1 Transgenic Mouse ModelMelatoninNeuroprotectionOxidative Stresshttps://purl.org/becyt/ford/1.6https://purl.org/becyt/ford/1In amyotrophic lateral sclerosis (ALS) reactive oxygen species and apoptosis are implicated in disease pathogenesis. Melatonin with its anti-oxidant and anti-apoptotic properties is expected to ameliorate disease phenotype. The aim of this study was to assess possible neuroprotection of melatonin in the G93A-copper/zinc superoxide dismutase (G93ASOD1) transgenic mouse model of ALS. Four groups of mice, 14 animals each, were injected intraperitoneally with 0 mg/kg, 0.5 mg/kg, 2.5 mg/kg and 50 mg/kg of melatonin from age 40 days. The primary end points were; disease onset, disease duration, survival and rotarod performance. No statistically significant difference in disease onset between the four groups was found. Survival was significantly reduced with the 0.5 mg/kg and 50 mg/kg doses and tended to be reduced with the 2.5 mg/kg dose. Histological analysis of spinal cords revealed increased motoneuron loss in melatonin treated mice. Melatonin treated animals were associated with increased oxidative stress as assessed with 4-hydroxynonenal (4-HNE), a marker of lipid peroxidation. Histochemistry and Western blot data of spinal cord from melatonin treated mice revealed upregulation of human SOD1 compared to untreated mice. In addition, real-time PCR revealed a dose dependent upregulation of human SOD1 in melatonin treated animals. Thus, intraperitoneal melatonin, at the doses used, does not ameliorate and perhaps exacerbates phenotype in the G93ASOD1 mouse ALS model. This is probably due to melatonin's effect on upregulating gene expression of human toxic SOD1. This action presumably overrides any of its direct anti-oxidant and anti-apoptotic properties.Fil: Dardiotis, Efthimios . The Cyprus Institute of Neurology and Genetics; ChipreFil: Panayiotou, Elena . The Cyprus Institute of Neurology and Genetics; ChipreFil: Feldman, Mariana Laura. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Córdoba. Instituto de Investigaciones Biológicas y Tecnológicas; ArgentinaFil: Hadjisavvas, Andreas . The Cyprus Institute of Neurology and Genetics; ChipreFil: Malas, Stavros . The Cyprus Institute of Neurology and Genetics; ChipreFil: Vonta, Ilia. National Technical University of Athens; GreciaFil: Hadjigeorgiou, Georgios . Centre for Research and Technology-Thessaly; GreciaFil: Kyriakou, Kyriakos . The Cyprus Institute of Neurology and Genetics; ChipreFil: Kyriakides, Theodoros . The Cyprus Institute of Neurology and Genetics; ChipreElsevier Ireland2013-08info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/13048Dardiotis, Efthimios ; Panayiotou, Elena ; Feldman, Mariana Laura; Hadjisavvas, Andreas ; Malas, Stavros ; et al.; Intraperitoneal melatonin is not neuroprotective in the G93ASOD1 transgenic mouse model of familial ALS and may exacerbate neurodegeneration; Elsevier Ireland; Neuroscience Letters; 548; 8-2013; 170-1750304-3940enginfo:eu-repo/semantics/altIdentifier/url/http://www.sciencedirect.com/science/article/pii/S0304394013005053info:eu-repo/semantics/altIdentifier/doi/10.1016/j.neulet.2013.05.058info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-nd/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-10-22T11:55:29Zoai:ri.conicet.gov.ar:11336/13048instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-10-22 11:55:29.841CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse |
dc.title.none.fl_str_mv |
Intraperitoneal melatonin is not neuroprotective in the G93ASOD1 transgenic mouse model of familial ALS and may exacerbate neurodegeneration |
title |
Intraperitoneal melatonin is not neuroprotective in the G93ASOD1 transgenic mouse model of familial ALS and may exacerbate neurodegeneration |
spellingShingle |
Intraperitoneal melatonin is not neuroprotective in the G93ASOD1 transgenic mouse model of familial ALS and may exacerbate neurodegeneration Dardiotis, Efthimios Amyotrophic Lateral Sclerosis G93asod1 Transgenic Mouse Model Melatonin Neuroprotection Oxidative Stress |
title_short |
Intraperitoneal melatonin is not neuroprotective in the G93ASOD1 transgenic mouse model of familial ALS and may exacerbate neurodegeneration |
title_full |
Intraperitoneal melatonin is not neuroprotective in the G93ASOD1 transgenic mouse model of familial ALS and may exacerbate neurodegeneration |
title_fullStr |
Intraperitoneal melatonin is not neuroprotective in the G93ASOD1 transgenic mouse model of familial ALS and may exacerbate neurodegeneration |
title_full_unstemmed |
Intraperitoneal melatonin is not neuroprotective in the G93ASOD1 transgenic mouse model of familial ALS and may exacerbate neurodegeneration |
title_sort |
Intraperitoneal melatonin is not neuroprotective in the G93ASOD1 transgenic mouse model of familial ALS and may exacerbate neurodegeneration |
dc.creator.none.fl_str_mv |
Dardiotis, Efthimios Panayiotou, Elena Feldman, Mariana Laura Hadjisavvas, Andreas Malas, Stavros Vonta, Ilia Hadjigeorgiou, Georgios Kyriakou, Kyriakos Kyriakides, Theodoros |
author |
Dardiotis, Efthimios |
author_facet |
Dardiotis, Efthimios Panayiotou, Elena Feldman, Mariana Laura Hadjisavvas, Andreas Malas, Stavros Vonta, Ilia Hadjigeorgiou, Georgios Kyriakou, Kyriakos Kyriakides, Theodoros |
author_role |
author |
author2 |
Panayiotou, Elena Feldman, Mariana Laura Hadjisavvas, Andreas Malas, Stavros Vonta, Ilia Hadjigeorgiou, Georgios Kyriakou, Kyriakos Kyriakides, Theodoros |
author2_role |
author author author author author author author author |
dc.subject.none.fl_str_mv |
Amyotrophic Lateral Sclerosis G93asod1 Transgenic Mouse Model Melatonin Neuroprotection Oxidative Stress |
topic |
Amyotrophic Lateral Sclerosis G93asod1 Transgenic Mouse Model Melatonin Neuroprotection Oxidative Stress |
purl_subject.fl_str_mv |
https://purl.org/becyt/ford/1.6 https://purl.org/becyt/ford/1 |
dc.description.none.fl_txt_mv |
In amyotrophic lateral sclerosis (ALS) reactive oxygen species and apoptosis are implicated in disease pathogenesis. Melatonin with its anti-oxidant and anti-apoptotic properties is expected to ameliorate disease phenotype. The aim of this study was to assess possible neuroprotection of melatonin in the G93A-copper/zinc superoxide dismutase (G93ASOD1) transgenic mouse model of ALS. Four groups of mice, 14 animals each, were injected intraperitoneally with 0 mg/kg, 0.5 mg/kg, 2.5 mg/kg and 50 mg/kg of melatonin from age 40 days. The primary end points were; disease onset, disease duration, survival and rotarod performance. No statistically significant difference in disease onset between the four groups was found. Survival was significantly reduced with the 0.5 mg/kg and 50 mg/kg doses and tended to be reduced with the 2.5 mg/kg dose. Histological analysis of spinal cords revealed increased motoneuron loss in melatonin treated mice. Melatonin treated animals were associated with increased oxidative stress as assessed with 4-hydroxynonenal (4-HNE), a marker of lipid peroxidation. Histochemistry and Western blot data of spinal cord from melatonin treated mice revealed upregulation of human SOD1 compared to untreated mice. In addition, real-time PCR revealed a dose dependent upregulation of human SOD1 in melatonin treated animals. Thus, intraperitoneal melatonin, at the doses used, does not ameliorate and perhaps exacerbates phenotype in the G93ASOD1 mouse ALS model. This is probably due to melatonin's effect on upregulating gene expression of human toxic SOD1. This action presumably overrides any of its direct anti-oxidant and anti-apoptotic properties. Fil: Dardiotis, Efthimios . The Cyprus Institute of Neurology and Genetics; Chipre Fil: Panayiotou, Elena . The Cyprus Institute of Neurology and Genetics; Chipre Fil: Feldman, Mariana Laura. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Córdoba. Instituto de Investigaciones Biológicas y Tecnológicas; Argentina Fil: Hadjisavvas, Andreas . The Cyprus Institute of Neurology and Genetics; Chipre Fil: Malas, Stavros . The Cyprus Institute of Neurology and Genetics; Chipre Fil: Vonta, Ilia. National Technical University of Athens; Grecia Fil: Hadjigeorgiou, Georgios . Centre for Research and Technology-Thessaly; Grecia Fil: Kyriakou, Kyriakos . The Cyprus Institute of Neurology and Genetics; Chipre Fil: Kyriakides, Theodoros . The Cyprus Institute of Neurology and Genetics; Chipre |
description |
In amyotrophic lateral sclerosis (ALS) reactive oxygen species and apoptosis are implicated in disease pathogenesis. Melatonin with its anti-oxidant and anti-apoptotic properties is expected to ameliorate disease phenotype. The aim of this study was to assess possible neuroprotection of melatonin in the G93A-copper/zinc superoxide dismutase (G93ASOD1) transgenic mouse model of ALS. Four groups of mice, 14 animals each, were injected intraperitoneally with 0 mg/kg, 0.5 mg/kg, 2.5 mg/kg and 50 mg/kg of melatonin from age 40 days. The primary end points were; disease onset, disease duration, survival and rotarod performance. No statistically significant difference in disease onset between the four groups was found. Survival was significantly reduced with the 0.5 mg/kg and 50 mg/kg doses and tended to be reduced with the 2.5 mg/kg dose. Histological analysis of spinal cords revealed increased motoneuron loss in melatonin treated mice. Melatonin treated animals were associated with increased oxidative stress as assessed with 4-hydroxynonenal (4-HNE), a marker of lipid peroxidation. Histochemistry and Western blot data of spinal cord from melatonin treated mice revealed upregulation of human SOD1 compared to untreated mice. In addition, real-time PCR revealed a dose dependent upregulation of human SOD1 in melatonin treated animals. Thus, intraperitoneal melatonin, at the doses used, does not ameliorate and perhaps exacerbates phenotype in the G93ASOD1 mouse ALS model. This is probably due to melatonin's effect on upregulating gene expression of human toxic SOD1. This action presumably overrides any of its direct anti-oxidant and anti-apoptotic properties. |
publishDate |
2013 |
dc.date.none.fl_str_mv |
2013-08 |
dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://purl.org/coar/resource_type/c_6501 info:ar-repo/semantics/articulo |
format |
article |
status_str |
publishedVersion |
dc.identifier.none.fl_str_mv |
http://hdl.handle.net/11336/13048 Dardiotis, Efthimios ; Panayiotou, Elena ; Feldman, Mariana Laura; Hadjisavvas, Andreas ; Malas, Stavros ; et al.; Intraperitoneal melatonin is not neuroprotective in the G93ASOD1 transgenic mouse model of familial ALS and may exacerbate neurodegeneration; Elsevier Ireland; Neuroscience Letters; 548; 8-2013; 170-175 0304-3940 |
url |
http://hdl.handle.net/11336/13048 |
identifier_str_mv |
Dardiotis, Efthimios ; Panayiotou, Elena ; Feldman, Mariana Laura; Hadjisavvas, Andreas ; Malas, Stavros ; et al.; Intraperitoneal melatonin is not neuroprotective in the G93ASOD1 transgenic mouse model of familial ALS and may exacerbate neurodegeneration; Elsevier Ireland; Neuroscience Letters; 548; 8-2013; 170-175 0304-3940 |
dc.language.none.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
info:eu-repo/semantics/altIdentifier/url/http://www.sciencedirect.com/science/article/pii/S0304394013005053 info:eu-repo/semantics/altIdentifier/doi/10.1016/j.neulet.2013.05.058 |
dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess https://creativecommons.org/licenses/by-nc-nd/2.5/ar/ |
eu_rights_str_mv |
openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by-nc-nd/2.5/ar/ |
dc.format.none.fl_str_mv |
application/pdf application/pdf |
dc.publisher.none.fl_str_mv |
Elsevier Ireland |
publisher.none.fl_str_mv |
Elsevier Ireland |
dc.source.none.fl_str_mv |
reponame:CONICET Digital (CONICET) instname:Consejo Nacional de Investigaciones Científicas y Técnicas |
reponame_str |
CONICET Digital (CONICET) |
collection |
CONICET Digital (CONICET) |
instname_str |
Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.name.fl_str_mv |
CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.mail.fl_str_mv |
dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar |
_version_ |
1846782258094014464 |
score |
12.982451 |